Skip to content
Bactobio logo — Bactobio uses advanced technology to harvest diverse chemica...

Bactobio

Bactobio uses advanced technology to harvest diverse chemicals from bacteria for medical and industrial use.

Founded 2020 United Kingdom London, United Kingdom 51 employees Total: $13.29M Biotechnology

General Information

Company Name Bactobio
Founded Year 2020
Location United Kingdom London, United Kingdom
Founders / Decision Makers
Team member
Employees 51
Industries Biotechnology
Business Model B2B, B2D, API
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Bactobio. To contact Bactobio, visit bacto.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Bactobio compare?

A PDF of Bactobio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Bactobio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Bactobio

Bactobio is a pioneering London-based biotechnology company established in 2020, driving innovation in the biotech sphere by leveraging advanced genomics, machine learning, and bioengineering. Their focus is on culturing the 99% of microbes that have been previously deemed unculturable, unlocking novel chemistries for effective, specific, and biodegradable applications.

Their proprietary technology holds significant promise in discovering new antibiotics to combat severe bacterial infections and facilitating sustainable plant protection solutions, aligning with both medical and industrial needs.

As of April 2023, Bactobio secured a £490.00K Grant investment, bolstering their capacity to advance their groundbreaking research. With its strategic headquarters in the United Kingdom, Bactobio is positioned at the forefront of the biotechnology industry, offering investors a unique opportunity to capitalize on their exclusive access to nature’s vast bioresource.

Business keywords: genomics, bioengineering, microbial culture, antibiotic discovery, antibiotic resistance, synthetic biology, next-generation sequencing, novel chemistries, plant protection, medical applications, industrial applications, environmental sustainability, pathogen targeting

Services & Products

Developing novel antimicrobials
Harnessing unculturable microbes
Unlocking new chemistries

Target Customers

Healthcare Industry Agricultural Sector

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Grant £490.00K -
01 Apr 2023
Early VC £6.00M 1
The Group Ventures
01 Dec 2022
Seed $3.80M -
01 Oct 2021
Seed $1.50M -
01 Nov 2020
Seed $1.50M -
01 Jun 2020
Spinout Undisclosed 1
University Ventures
01 Jan 2020

Bactobio Alternatives & Competitors

View All Alternatives
Bactobio vs
BaseClear
BaseClear The Netherlands

Molecular Intelligence. Clearer Decisions.

66 employees
Biotechnology
Bactobio vs
Earlham Institute
Earlham Institute United Kingdom

We harness the power of data-driven biology to accelerate solutions for health, biodiversity and foo...

142 employees
Biotechnology, Life Sciences
Bactobio vs

CRO | Animal Cell Culture | Genomics | Drug Discovery| Nanobiotech| Phytochemistry| Analytical Servi...

64 employees
Biotechnology

FAQ About Bactobio

Bactobio uses advanced technology to harvest diverse chemicals from bacteria for medical and industrial use.
Bactobio was founded in 2020.
Bactobio is headquartered in London, United Kingdom.
Bactobio operates in Biotechnology. Its work centres on genomics, bioengineering, microbial culture and antibiotic discovery. Its customers include Healthcare Industry and Agricultural Sector.
Bactobio has a B2B, B2D and API business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Bactobio has approximately 51 employees.
Bactobio has completed 6 funding rounds, raising a total of $13.29M.
Bactobio offers: Developing novel antimicrobials, Harnessing unculturable microbes, Unlocking new chemistries.
Top alternatives and competitors to Bactobio include BaseClear, Earlham Institute, BioNome Research and Solutions, Peptobiotics, Sentebiolab Biotechnology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bactobio and BaseClear are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bactobio, https://www.bouncewatch.com/company/bactobio, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout